Heart failure & cardiomyopathies
Heart failure with improved versus persistently reduced left ventricular ejection fraction: A comparison of the BIOSTAT‐CHF (European) study with the ASIAN‐heart failure (HF) registry
Main finding · HF rehospitalisation or all-cause mortality (composite)Result — go to the resultHazard ratio 0.46 95% CI 0.30–0.70Authors' conclusion
Approximately 20-30% of patients with HFrEF improved to HFimpEF within 1 year with better clinical outcomes. In addition, the predictive model with clinical predictors could more accurately predict HFimpEF in patients with HFrEF.
Study context
- Population
- Patients with HF and left ventricular ejection fraction (LVEF) ≤40% at baseline with LVEF re-assessed at 9 months (BIOSTAT-CHF; validation ASIAN-HF registry)
- Exposure
- HFimpEF vs persistent HF with reduced ejection fraction (HFrEF)
- Outcome
- Composite of:
- Time to HF rehospitalization
- All-cause mortality
Methodological detailsvalidation in ASIAN-HF registry
- Validation in ASIAN-HF registry
Main finding
As reported in the abstract
HF rehospitalisation or all-cause mortality (composite)
Hazard ratio
0.46
95% CI 0.30–0.70
P < 0.001
HFimpEFvs HFrEF
HR 0.46 (95% CI 0.30–0.70); P < 0.001
- Similar in ASIAN-HF validation cohort, composite endpoint: HR 0.29, 95% CI 0.17-0.48
- P < 0.001
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| All-cause mortalityBIOSTAT-CHF | 0.52 (0.28–0.97) | P = 0.040 | |
| 0.20.5125Hazard ratio (log scale) |
- All-cause mortality — Similar in ASIAN-HF validation cohort, all-cause mortality: HR 0.40, 95% CI 0.18-0.89
- p = 0.024
Original publication
Heart failure with improved versus persistently reduced left ventricular ejection fraction: A comparison of the BIOSTAT‐CHF (European) study with the ASIAN‐HF registry. Eur J Heart Fail. Published 9 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →